OneCell Diagnostics, a genomics-based precision oncology company, has raised $16 million in its Series A funding round led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
The funds raised will be used to advance its vision of democratizing precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable.
Additionally, OneCell will expand to the U.S. market with its liquid biopsy test, OncoIndx Ikon. The test detects and analyzes CTCs, which offer rich biomarkers that advance precision diagnosis and treatment of cancer for use cases including treatment response monitoring, disease progression, recurrence, and more.
Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr James Rothman will join the OneCell board of directors.
“We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision. By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalized cancer care worldwide,” said Mohan Uttarwar, CEO and Co-founder at OneCell Diagnostics.
“Celesta is excited about differentiated companies sitting at the intersection of high tech and biomedical science, and OneCell fits this mold perfectly. By leveraging the strategic benefits of the U.S.-India corridor, OneCell is well-positioned to continue building competitive advantages. We pride ourselves on being active value-add investors and Celesta will tap our ecosystem to support their growth wherever possible,” said Michael Marks, Founding Managing Partner at Celesta Capital.
“I’m looking forward to joining the OneCell Board at such a pivotal time in the arc of innovation for cancer treatment. Cell biopsy represents a groundbreaking shift in how we approach diagnostics, creating more opportunities for highly individualized care. This technology has the potential to reshape the oncology landscape, and we are eager to support OneCell’s bold mission to reach more than 1000 oncologists and 1 million patients in the near future,” said Dr James Rothman, Nobel Laureate and Celesta Capital Advisor.
Founded in 2021, OneCell Diagnostics is a genomics-based precision oncology company, that provides comprehensive genomic solutions for better cancer management. OneCell’s proprietary technology leverages a combination of next-generation sequencing in combination with strong bioinformatics, AI / ML, and data analytics for multi-omics biomarkers.
